Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia | Journal of Hematology & Oncology | Full Text
The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials - Mocquot - 2022 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library
Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies | Journal for ImmunoTherapy of Cancer
FDA Approves Blincyto (blinatumomab) for Precursor B-Cell Acute Lymphoblastic Leukemia | New Drug Approvals
Addgene: pHR_Gal4UAS_Blinatumomab_PGK_mCherry
Gene structure and production of bispecific blinatumomab diabody. DNA... | Download Scientific Diagram
A and B) Diagram of blinatumomab structure 30 consisting of variable... | Download Scientific Diagram
Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia | Blood Cancer Journal
Blinatumomab - an overview | ScienceDirect Topics
PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia | Science Advances
125557Orig1s000
Blinatumomab structure. Variable regions of anti-CD19 and anti-CD3... | Download Scientific Diagram
Blinatumomab: A Step Forward in the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia
A high throughput bispecific antibody discovery pipeline | bioRxiv
The Epigenetic Regulation of Blinatumomab Gene Expression: Tumor Cell-dependent T cell Response against Lymphoma Cells and Cytot
Amgen Presents Data From Three Trials Evaluating BLINCYTO® (blinatumomab) In Acute Lymphoblastic Leukemia At ASH 2015
Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy. - Document - Gale Academic OneFile
Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial - The Lancet Haematology
Blinatumomab-induced T cell activation at single cell transcriptome resolution | BMC Genomics | Full Text
Cancers | Free Full-Text | Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab
Blinatumomab: structure and mode of action. Notes: (A) Blinatumomab... | Download Scientific Diagram
Blinatumomab: structure and mode of action. Notes: (A) Blinatumomab... | Download Scientific Diagram
Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab - ScienceDirect
Blinatumomab: A historical perspective - ScienceDirect
